Xenolis Pte. Ltd. utilizes its proprietary ExSELEX™ platform to develop XenoAptamers, which are synthetic oligonucleotides featuring unnatural base pairs that enhance target affinity and specificity. This technology addresses the need for highly customizable nucleic acids in diagnostics, biosensing, and therapeutics across various life science applications.
Funding
Funding not disclosed
Founders
Product
Problem
Conventional aptamers, composed of naturally occurring nucleotides, can sometimes lack the necessary affinity and specificity for certain biological targets, limiting their effectiveness in diagnostic, biosensing, and therapeutic applications. The chemical diversity of natural nucleic acids can restrict their ability to bind tightly and selectively to complex or structurally similar molecules.
Solution
Xenolis Pte. Ltd. utilizes its proprietary ExSELEX™ platform to develop XenoAptamers, synthetic oligonucleotides that incorporate unnatural base pairs, expanding the genetic alphabet beyond the standard four letters. These XenoAptamers exhibit enhanced target affinity and specificity compared to traditional aptamers, enabling more precise and effective applications in diagnostics, biosensing, and therapeutics. The ExSELEX™ platform facilitates the creation of highly customizable nucleic acids tailored to specific research, discovery, and clinical needs. By introducing chemical diversity through unnatural base pairs, Xenolis overcomes limitations associated with natural nucleic acids, leading to improved binding characteristics and broader applicability.
Target Audience
The primary customers are researchers, biopharmaceutical companies, and diagnostic developers seeking high-affinity, high-specificity nucleic acids for various life science applications.
Features
- ExSELEX™ platform: A proprietary technology for generating XenoAptamers with unnatural base pairs.
- XenoAptamers: Synthetic oligonucleotides with enhanced affinity and specificity due to unnatural base pairs.
- Six-letter DNA alphabet: Utilizes an unnatural base pair system for expanded genetic diversity.
- Customizable design: Tailored XenoAptamers for specific targets and applications.
- Characterization: Affinity and specificity evaluation using Surface Plasmon Resonance (SPR).
- Workflow: Feasibility study, selection, and characterization for customized XenoAptamer development.